



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006,235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

SML/201/2013-14

Date:09.11.2013

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex,Bandra (E)
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Un-audited Financial Results with Limited Review Report.

Ref: Symbol: SHILPAMED, Series: EQ

We are herewith enclosing Un-audited Financial Results of the Company for the quarter ended on 30th September 2013 along with Limited Review Report.

Kindly receive the same & acknowledge.

Thanking you,

Yours faithfully,

For **SHILPA MEDICARE LIMITED**


RAMAKANT INNANI
COMPLIANCE OFFICER



Encl: As Above.



SHILPA MEDICARE LIMITED

Regd. Office: # 10/80, First Floor, Rajendra Gunj, Raichur-584102 (Karnataka)
UNAUDITED FINANCIAL RESULTS FOR 2ND QUARTER AND HALF YEAR ENDED 30TH SEPT -2013

PART-I

Amount / Rs in laacs

	Particulars	Quarter Ended						Year to date six months ended				Previous Year (Audited)	
		Standalone			Consolidated			Standalone		Consolidated		Standalone	Consolidated
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	30.09.2013	30.09.2012	31.03.13	31.03.13
1	Income from operations												
	(a) Net sales/income from operations (Net of Excise Duty)	12761.48	10291.38	8073.46	13589.73	11369.33	9025.27	23052.86	15735.71	24959.06	17875.92	32819.59	37132.34
	(b) Other operating revenues	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total income from operations (net)	12761.48	10291.38	8073.46	13589.73	11369.33	9025.27	23052.86	15735.71	24959.06	17875.92	32819.59	37132.34
2	Expenses												
	(a) Cost of materials consumed	7568.81	5490.66	6470.28	7926.17	5764.87	6698.37	13059.46	10415.34	13691.03	10934.55	19909.50	20904.52
	(b) Purchases of stock-in-trade	150.29	40.46	20.81	163.52	40.46	20.81	190.74	204.90	203.99	204.90	263.10	263.10
	(c) Changes in inventories of finished goods, WIP, Stock in Trade	-592.15	102.24	-1335.52	-724.55	-13.17	-1306.94	-489.92	-869.06	-737.71	-866.89	370.77	318.99
	(d) Employee benefits expense	958.03	850.17	639.03	1606.58	1412.90	1120.23	1808.20	1223.23	3019.48	2164.46	2559.86	4551.27
	(e) Depreciation and amortisation expense	524.17	495.94	319.23	580.21	546.24	400.51	1020.11	626.03	1126.45	788.55	1275.36	1533.99
	(f) Other expenses	1905.43	1733.87	450.75	2217.75	2030.46	663.56	3639.30	1485.87	4248.21	1933.94	3234.20	4207.68
	Total Expense	10514.58	8713.33	6564.58	11769.68	9781.76	7596.54	19227.89	13086.31	21551.45	15159.51	27612.79	31779.55
3	Profit/(Loss) from Operations before Other Income, Finance Costs & exceptional items (1-2)	2246.90	1578.05	1508.88	1820.05	1587.57	1428.73	3824.97	2649.40	3407.61	2716.41	5206.80	5352.79
4	Other Income	172.11	455.68	170.18	140.89	443.70	146.56	627.79	296.78	584.59	275.22	500.64	501.05
5	Profit/(Loss) from Ordinary activities before finance cost & exceptional items (3+/-4)	2419.01	2033.73	1679.06	1960.94	2031.27	1575.29	4452.76	2946.18	3992.20	2991.63	5707.44	5853.84
6	Finance costs	99.03	75.44	33.81	100.43	77.12	37.03	174.48	68.60	177.54	71.94	135.94	143.60
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5 +/- 6)	2319.98	1958.29	1645.25	1860.51	1954.15	1538.26	4278.28	2877.58	3814.66	2919.69	5571.50	5710.24
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit/(Loss) from Ordinary Activities before tax (7 +/- 8)	2319.98	1958.29	1645.25	1860.51	1954.15	1538.26	4278.28	2877.58	3814.66	2919.69	5571.50	5710.24
10	Tax expense	557.05	274.29	393.81	551.17	271.78	392.22	831.35	692.03	822.95	703.11	965.18	953.08
11	Net Profit/(Loss) from ordinary activities after tax	1762.93	1684.00	1251.44	1309.34	1682.37	1146.04	3446.93	2185.55	2991.71	2216.58	4606.32	4757.16
12	Extraordinary Items Income / (Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10.37	-10.37
13	Net Profit/(Loss) for the period (11+12)	1762.93	1684.00	1251.44	1309.34	1682.37	1146.04	3446.93	2185.55	2991.71	2216.58	4595.95	4746.79
14	Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Add:(Gain)/ loss pertaining to Minority Interest	0.00	0.00	0.00	50.28	11.30	-6.90	0.00	0.00	38.98	-7.47	0.00	-12.32
16	Net Profit / (loss) after taxes, minority interest and share of profit/(loss) of associates (13+/-14+/-15)	1762.93	1684.00	1251.44	1359.62	1693.67	1139.14	3446.93	2185.55	3030.69	2209.11	4595.95	4734.47
17	Paid-up equity share capital (Face value of Rs 2/-)	735.72	735.72	490.48	735.72	735.72	490.48	735.72	490.48	735.72	490.48	490.48	490.48
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	-	-	-	-	32588.13	31551.98
19.i	Earnings Per Share (EPS) (before extraordinary items)												
	(of Rs.2/- each) (not annualized):												
	a) Basic	4.79	4.58	5.10	3.70	4.60	4.64	9.37	8.91	8.24	9.01	18.78	19.40
	b) Diluted	4.79	4.58	5.10	3.70	4.60	4.64	9.37	8.91	8.24	9.01	18.78	19.40
19.ii	Earnings Per Share (EPS) (after extraordinary items)												
	(of Rs.2/- each) (not annualized):												
	a) Basic	4.79	4.58	5.10	3.70	4.60	4.64	9.37	8.91	8.24	9.01	18.74	19.36
	b) Diluted	4.79	4.58	5.10	3.70	4.60	4.64	9.37	8.91	8.24	9.01	18.74	19.36

PART-II

A. PARTICULARS OF SHARE HOLDING													
1	Public Shareholding	16229589	16229589	10819724	16229589	16229589	10819724	16229589	10819724	16229589	10819724	10819724	10819724
	- Number of Shares	44.12	44.12	45.04	44.12	44.12	45.04	44.12	45.04	44.12	45.04	44.12	44.12
2	Promoters & Promoters group Shareholding**												
	a) Pledged / Encumbered												
	- Number of shares	0	0	0	0	0	0	0	0	0	0	0	0
	- Percentage of shares (as a % of the total of promoter and promoter group)	-	-	-	-	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share holding of the company)	-	-	-	-	-	-	-	-	-	-	-	-
	b) Non encumbered												
	- Number of shares	20556658	20556658	13204441	20556658	20556658	13204441	20556658	13204441	20556658	13204441	13704441	13704441
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share holding of the company)	55.88	55.88	54.96	55.88	55.88	54.96	55.88	54.96	55.88	54.96	55.88	55.88
B. PARTICULARS OF INVESTOR COMPLAINTS													
Particulars		Six Months ended 30th September, 2013											
Pending at the beginning of the quarter		Nil											
Received during the quarter		35											
Disposed off during the quarter		35											
Unresolved at the end of the quarter		Nil											

Notes:

- The Unaudited Financial Results have been reviewed by the Audit Committee and approved at the meeting of the Board of Directors and have undergone Limited Review by the Statutory Auditors.
- As per AS-17 reportable segment is only one as the company considered its present business as one inter related and integrated business of 'Pharmaceutical Products'.
- Tax Expense includes Current Tax and Deferred Tax.
- Mat Credit of Rs 164.55 Lakhs has been recognized for the quarter, since the company is liable to pay tax under section.115JB of the Income Tax Act 1961.
- Capital Advances includes a sum of Rs.407.61 paid towards supply of machinery for its Formulation project. Due to inordinate delay by vendor, the Company terminated its order and filed a law suit for recovery amount alongwith interest and damages with the local court in Canada. The preliminary hearing and recovery proceeding are under process. As the outcome of the case cannot be determined presently the Company has not made any provision.
- Other expenses includes foreign exchange Loss /(Gain) of Rs 958.55 lacs in period ended 30.09.2013 and (726.10) in period ended 30.09.2012.
- Figures of the previous year/quarter have been regrouped/rearranged wherever necessary.
- Share capital has increase due to issue of 12262082 equity shares as bonus shares


Place:Hyderabad

Date:09.11.2013

For SHILPA MEDICARE LIMITED



Vishnukant C. Bhutada
Managing Director





SHILPA MEDICARE LIMITED

Regd.Office: # 10/80, First Floor,Rajendra Gunj, Raichur-584102(Karnataka)

STANDALONE/CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2013

(Rs. In lacs)

Particulars	Standalone		Consolidated	
	30.09.2013	31.03.2013	30.09.2013	31.03.2013
	Unaudited	Audited	Unaudited	Audited
A. EQUITY AND LIABILITIES				
1. Shareholder's funds				
(a) Share Capital	735.72	490.48	735.72	490.48
(b) Reserves and Surplus	36454.21	32588.13	34690.32	31551.98
Sub.total-Shareholder's funds	37189.93	33078.61	35426.04	32042.46
2. Minority Interest	0.00	0.00	833.18	872.14
3. Non-Current Liabilities				
(a) Long-term borrowings	4066.68	4321.86	7210.45	7046.55
(b) Deferred tax liabilities (net)	2433.46	2063.02	2453.57	2092.21
(c) Long-term provisions	37.24	31.24	893.46	692.29
(d) Other Non-Current Liabilities	0.00	0.00	70.84	19.51
Sub.total-Non-current liabilities	6537.38	6416.12	10628.32	9850.56
4. Current Liabilities				
(a) Short-term borrowings	90.96	3892.33	1168.76	4506.59
(b) Trade payables	9442.65	4884.84	9832.73	5237.20
(c) Other current liabilities	2903.07	2039.73	3233.30	2227.08
(d) Short-term provisions	11.86	379.98	66.33	406.05
Sub.total-Current liabilities	12448.54	11196.88	14301.12	12376.92
TOTAL-EQUITY AND LIABILITIES	56175.85	50691.61	61188.65	55142.08
B. ASSETS				
1. Non-current Assets				
(a) Goodwill on Consolidation	0.00	0.00	593.68	523.46
(b) Fixed assets (Net Block)				
(i) Tangible /Intangible assets	26144.89	15255.58	28601.99	17543.57
(ii) Capital work-in-progress	2262.91	11427.15	6369.88	12915.35
	28407.80	26682.73	35565.55	30982.38
(c) Non current investments	5400.42	3700.73	582.13	14.12
(d) Other non current assets	0.00	0.00	23.08	25.15
(e) Long-term loans and advances	2623.33	2039.07	3261.52	2921.64
Sub.total-Non-current assets	36431.55	32422.53	39432.28	33943.29
2. Current Assets				
(a) Current investments	2001.46	5028.16	2001.45	5028.16
(b) Inventories	8390.89	6612.96	9676.55	7433.24
(c) Trade receivables	5203.53	3187.68	6043.42	4178.79
(d) Cash and cash equivalents	117.28	1052.55	2109.33	3043.27
(e) Short-term loans and advances	3892.08	2309.27	1751.99	1358.43
(f) Other current assets	139.06	78.46	173.63	156.90
Sub.total-Current assets	19744.30	18269.08	21756.37	21198.79
TOTAL-ASSETS	56175.85	50691.61	61188.65	55142.08

By the order of the Board of Directors
for SHILPA MEDICARE LIMITED

Vishnukant.C. Bhutada
Managing Director




Place:Hyderabad
Date: 09.11.2013

Limited Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of
Shilpa Medicare Limited

1. We have reviewed the quarterly unaudited financial results of **Shilpa Medicare Limited** for the quarter ended **30th September, 2013** attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. **Matter of Emphasis**
Without qualifying our review report on financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.407.61 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The Preliminary hearings of the case are in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.
4. Based on our review conducted and subject to Matter of emphasis mentioned at Point No.03 above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bohara Bhandari Bung & Associates
Chartered Accountants
(Firm Regn No. 008127S)


CA. Pankaj Kumar Bohara
Partner
M.No: 215471



Place: Hyderabad
Date: 09.11.2013

**Limited Review Report on Unaudited Quarterly Consolidated Financial Results of the
Company Pursuant to the Clause 41 of the Listing Agreement**

To
Board of Directors of
Shilpa Medicare Limited

1. We have reviewed the Unaudited quarterly consolidated financial results of **Shilpa Medicare Limited** ('the Company'), its Subsidiaries ("Collectively known as Group") for the quarter ended **30th September, 2013** attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our review
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Further, these Consolidated Financial Statements does not include the share of profits/loss of M/s. Maia Pharmaceuticals Inc., USA, an Associate Company and therefore Consolidated profit / loss of the Company are subject to the above.

3. Matter of Emphasis

Without qualifying our review report on financial results, we state that the Company has filed a lawsuit for recovering its amount of Rs.407.61 Lakhs which is paid as capital advance to its vendor for supply of Capital Asset, along with punitive damages. The Preliminary hearings of the case are in progress. The ultimate outcome of the matter cannot presently be determined, and hence no provision for the outstanding balance receivable from the party has been made in the financial statements. Our Report is not qualified on this matter.

4. Further, we did not review the financial statements of 04 subsidiaries included in the Unaudited consolidated quarterly financial results, whose financial statements reflect total assets of Rs.8,288.04 Lakhs as at 30th September, 2013, as well as the total revenue of Rs.862.08 Lakhs and Net profit / (Loss) after tax of Rs.(337.28)Lakhs for the quarter ended 30th September, 2013. These financial statements and other financial information have not been reviewed by their auditors. These financial result have been certified by the company's management and furnished to us, and our opinion, in so far as it relates to the amount included in respect of the 4 subsidiaries, are based solely on these certified financial results.



BOHARA BHANDARI BUNG AND ASSOCIATES
CHARTERED ACCOUNTANTS

CA. BOHARA. S.J. B. Com., FCA

CA. BHANDARI. P.M. B.Com., FCA


CA. BUNG. R.S. B.Com., FCA

CA. PANKAJ KUMAR BOHARA. B. Com., ACA, DISA

☎ : (08532) 231902, 230221, 231183, 232403
AMAR COMPLEX, 1ST FLOOR,
NO. 11-1-137, M.G. ROAD,
RAICHUR - 584 101

5. Based on our review conducted and Matter of Emphasis mentioned above in point no.03 nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bohara Bhandari Bung & Associates.
Chartered Accountants
(Firm Regn No. 008127S)


CA. Pankaj Kumar Bohara
Partner
M.No. 215471



Place: Hyderabad
Date: 09.11.2013